Skip to content

Impact of Different Domperidone Dosages on Reflux Esophagitis Treated with Esomeprazole: A Randomized Controlled Trial

Impact of Different Domperidone Dosages on Reflux Esophagitis Treated with Esomeprazole: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260417013
Enrollment
361
Registered
2026-04-17
Start date
2022-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux Esophagitis Esomeprazole

Interventions

The standard esomeprazole (Astrazeneca, National Drug Approval No. H20046380, 40mg per tablet) treatment is administered at a dose of 40mg once daily, 30 minutes before meals, for a course of 8 weeks,
Active Comparator Drug,Experimental Drug,Experimental Drug,Experimental Drug
control group,low-dose group,medium-dose group,high-dose group

Sponsors

Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Have good compliance with the prescribed treatment and follow-up procedures; (2) Agreed to participate in this study and signed the informed consent; (3) Meet the above-mentioned diagnostic criteria for RE; (4) Aged > 18 years.

Exclusion criteria

Exclusion criteria: (1) gastrointestinal bleeding, malignant tumor, long-segment Barrett's esophagus, esophageal stricture, esophageal varices, endoscopically confirmed esophageal stricture, or eosinophilic esophagitis; (2) a history of gastrointestinal surgery (apart from endoscopic resection); (3) an allergy to antacids or PPIs; (4) Malignant tumor history within the previous five years; (5) Patients with severe respiratory, central nervous, endocrine, or cardiovascular system diseases; (6) Having diseases of the liver or kidneys that are clinically important; (7) Women who are pregnant or nursing; (8) Those who have a history of mental illness; (9) Those who intend to be hospitalized or have surgery during the study period.

Design outcomes

Primary

MeasureTime frame
endoscopic remission rate at 8-week Endoscope

Secondary

MeasureTime frame
symptom scores before and after treatment Gastroesophageal Reflux Disease Questionnaire,quality of life before and after treatment GERD-Health Related Quality of Life (GERD-HRQL) scale

Countries

China

Contacts

Public ContactYe Zhao

Beijing Hospital of Integrated Traditional Chinese and Western Medicine

Zhaoye9500@163.com15801209500

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026